


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-15. (cancelled)

16. (new) A nitrogeneous polycyclic derivative, said derivative having formula
(I)



wherein

$m = 1, 2$ or 3

R_n is anyone of R_1 , R_2 , R_3 and R_4 , which are identical or different and represent H or represent one or several radicals and are selected in the group comprising OH, an alkyl radical, O-alkyl group, NH_2 , NH-alkyl, $N(R_5, R_6)$, the alkyl being in said radical or groups a C1-C6 alkyl, or an halogen selected between the group consisting of F, Cl, Br,

Y

forms a phenyl group with both pyridines, optionally ortho-substituted by a substituent R5, or orthodisubstituted by R5 and R6, said substituents being identical or different, and selected in the group comprising an alkyl radical, O-alkyl group, NH₂, NH-alkyl, N(R5, R6), the alkyl being in said radical or groups a C1-C6 alkyl, or an halogen selected between the group consisting of F, Cl, Br

or

represents a group - (CH₂)_{m1}-W-(CH₂)_{m2}-, with m1 and m2 being 0, 1 or 2 and W being a group CH₂, CH(R7), O, or N(R8), R7 and R8 being a C1-C3 alkyl radical, or H,

Z is a linking arm of formula -A-(CH₂)_n-U-(CH₂)_n-A-

A being O or NH, and

U being selected in the group comprising (CH₂)_{n1}, CHN (R1, R2), CHCOOH, CHOH

with n being a number from 1 to 6, preferably from 2 to 4, and n1 being 0 or 1,

and the complexes thereof with transition metals, particularly with copper, zinc or iron.

17. (new) The derivative of claim 16, wherein said derivative includes 2 cyclic moieties.


18. (new) The derivative of claim 16, wherein said derivative includes a 3 cyclic

moieties.

19. (new) The derivative of claim 16, wherein said derivative includes 4 cyclic moieties.

20. (new) The derivative of claim 16, wherein, in said derivative, the cyclic moieties consist of Phen moieties.

21. (new) The derivative of claim 20, wherein said derivative is apolycyclic Phen having formula (II)



22. (new) A method of preparing a drug composition for treating a neurodegenerative disease comprising admixing a derivative of claim 16 and a pharmaceutically insert vehicle, said disease preferably being selected from Alzheimer,

Parkinson, or Huntington diseases.

23. (new) A composition comprising a derivative of claim 16, and a pharmaceutical inert vehicle.


24. (new) The composition of claim 23, in the form of a an orally, intramuscularly or intravenously administrable composition.

25. (new) The composition of claim 24, wherein, said form is a tablet, a pill, a capsule drops, a patch, or a spray.

26. (new) The composition of claim 24, wherein said form is an injectible composition administrable by the intravenous, subcutaneous or intramuscular route, said composition further containing sterile or sterilisable solution, or suspension or emulsion.


27. (new) A method of making a derivative of claim 16, comprising reacting

- a dihydroxy bipyridine derivative of formula (III)



with

- ditosyl derivative of formula (IV)



28. (new) The method of claim 27, wherein the reaction is carried out with high dilution conditions.

29. (new) The method of claim 27, comprising the use of cesium carbonate.

30. (new) A method of chelating a transition metal comprising admixing a derivative of claim 16 with said metal.

31. (new) A method of treating a neurodegenerative disease comprising administering a derivative of claim 16 to a person in need of said treatment.

32. (new) The method of claim 31 wherein said disease is selected from the group of Alzheimer disease, Parkinson disease, and Huntington diseases.